https://scholars.lib.ntu.edu.tw/handle/123456789/620212
Title: | Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors | Authors: | Park K. Tan D.S.W. Su W.-C. Cho B.C. Kim S.-W. Lee K.H. Wang C.-C. Seto T. Huang D.C.-L. Jung H.H. Hsu M.-C. Bogenrieder T. CHIA-CHI LIN |
Issue Date: | 2021 | Publisher: | Elsevier Inc. | Journal Volume: | 2 | Journal Issue: | 9 | Start page/Pages: | 100206 | Source: | JTO Clinical and Research Reports | URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85122741646&doi=10.1016%2fj.jtocrr.2021.100206&partnerID=40&md5=8538b6bbe9ff63701f22e2c3e48f0595 https://scholars.lib.ntu.edu.tw/handle/123456789/620212 |
ISSN: | 2666-3643 | DOI: | 10.1016/j.jtocrr.2021.100206 |
Appears in Collections: | 臨床醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.